CP and Hypertension: 31 clinical studies involving two or more COVID-19 patients of different ages (14-91 years) and disease severity (eg, hospitalized, moderate, severe, or life-threatening), either previously healthy or with comorbidities (cancer, hypertension, immunosuppression, organ transplantation) that were treated with various doses of CP (200 mL to 3 × 200 mL) in addition to supportive care, antiviral therapy, antibiotics, steroids, or anticoagulation treatment.